Billiontoone (NASDAQ:BLLN) Price Target Cut to $130.00 by Analysts at BTIG Research

Billiontoone (NASDAQ:BLLN) had its price objective decreased by investment analysts at BTIG Research from $140.00 to $130.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price objective points to a potential upside of 59.71% from the stock’s current price.

A number of other brokerages have also recently commented on BLLN. Wells Fargo & Company cut their price target on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research note on Thursday, March 5th. Guggenheim lowered their price objective on shares of Billiontoone from $120.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Wall Street Zen upgraded shares of Billiontoone from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Billiontoone in a report on Friday, May 1st. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $125.29.

Billiontoone Stock Up 1.9%

NASDAQ:BLLN opened at $81.40 on Thursday. Billiontoone has a twelve month low of $61.96 and a twelve month high of $138.70. The firm has a market cap of $3.74 billion and a price-to-earnings ratio of 387.62. The company has a debt-to-equity ratio of 0.12, a current ratio of 11.69 and a quick ratio of 11.32. The business’s 50 day moving average is $77.51.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.01 by $0.33. During the same period last year, the company posted ($0.39) earnings per share. The business’s quarterly revenue was up 83.8% on a year-over-year basis. As a group, analysts anticipate that Billiontoone will post 0.42 earnings per share for the current year.

Hedge Funds Weigh In On Billiontoone

Institutional investors and hedge funds have recently modified their holdings of the stock. Baillie Gifford & Co. acquired a new position in Billiontoone in the 4th quarter valued at about $103,786,000. Massachusetts Financial Services Co. MA bought a new position in shares of Billiontoone during the fourth quarter worth approximately $13,373,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Billiontoone during the 4th quarter worth approximately $1,348,000. FNY Investment Advisers LLC bought a new stake in Billiontoone in the 4th quarter valued at $497,000. Finally, Green Alpha Advisors LLC acquired a new position in Billiontoone in the 4th quarter valued at $436,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.